[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641088":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":37,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":7,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":59,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","indubufen, aspirin, clopidogrel, cilostazol","Dosage, Frequency: Indobufen (200 mg twice daily); Aspirin (100 mg once daily); Cilostazol (100 mg twice daily); Clopidogrel (75 mg once daily). Dual antiplatelet therapy (DAPT) with two of these agents was permitted if clinically indicated, as per the treating physician's judgment.",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Jia Yin","CONTACT","13802964883","jiajiayin@139.com",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Jiayin Chen","13337523808","liuqiruismu@gmail.com",[24],{"facility":25,"status":7,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":7},"Nanfang Hospital,Southern Medical University Recruiting","Guangzhou","Guangdong","510515","China","CN",{"type":32,"coordinates":33},"Point",[34,35],113.25,23.11667,{"lat":35,"lon":34},{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100641088","efficacy-and-safety-of-indobufen-aspirin-cilostazol-and-clopidogrel-in-the-treatment-of-ischemic-stroke-100641088",false,"NCT07604298","Efficacy and Safety of Indobufen, Aspirin, Cilostazol and Clopidogrel in the Treatment of Ischemic Stroke","Efficacy and Safety of Indobufen, Aspirin, Cilostazol, and Clopidogrel in the Treatment of Ischemic Stroke: a Single-center, Retrospective Study","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Diagnosed with acute ischemic stroke (AIS) patients according to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018 ;\n3. Hospitalized in the Department of Neurology, Nanfang Hospital, Southern Medical University, between January 2020 and December 2025;\n4. Received one of the following as a secondary prevention regimen within 7 days after discharge: indobufen, aspirin, clopidogrel, or cilostazol, either as monotherapy or as dual therapy;\n5. Have follow-up records at 1 year after treatment initiation.\n\nExclusion Criteria:\n\n1. Already having long-term anticoagulant therapy at baseline;\n2. History of hemorrhagic stroke or active bleeding;\n3. Severe hepatic or renal dysfunction (defined as AST\u002FALT \\> 3 times the upper limit of normal, or estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73m²), end-stage disease, intracranial tumor, or intracranial infection.","ALL","18 Years",{"count":49,"type":50},2000,"ESTIMATED","OBSERVATIONAL","Through a single-center retrospective cohort study of acute ischemic stroke (AIS) patients receiving secondary prevention with indobufen, clopidogrel, cilostazol, or aspirin as monotherapy or dual therapy, we aim to compare the real-world effectiveness and safety of these four antiplatelet regimens. Through closely tracking the recurrence of stroke (including ischemic and hemorrhagic stroke) and bleeding events (GUSTO-defined) within one year of treatment, we evaluate the association between each antiplatelet agent and the risk of stroke recurrence, thereby providing critical evidence to guide individualized antiplatelet therapy in AIS patients.",[54],"Acute Ischemic Stroke",[56,57,58],"Stroke recurrence","Antiplatelet therapy","Secondary prevention","NOT_YET_RECRUITING","2026-05-18",{"date":62,"type":63},"2026-05-22","ACTUAL",{"date":65,"type":50},"2026-07-01",{"date":67,"type":50},"2027-06-01",{"name":5,"class":6},1]